EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$18.29

Market cap

$5.93B

P/E Ratio

32.09

Dividend/share

N/A

EPS

$0.57

Enterprise value

$5.62B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The company's equity rose by 13% YoY
The revenue has grown by 12% YoY
The company's EPS fell by 41% QoQ and by 22% YoY
The company's net income fell by 41% QoQ and by 21% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN JNJ

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
324.09M
Market cap
$5.93B
Enterprise value
$5.62B
Valuations
Price to earnings (P/E)
32.09
Price to book (P/B)
2.37
Price to sales (P/S)
3.65
EV/EBIT
23.97
EV/EBITDA
20.53
EV/Sales
3.49
Earnings
Revenue
$1.61B
EBIT
$234.35M
EBITDA
$273.54M
Free cash flow
$334.91M
Per share
EPS
$0.57
Free cash flow per share
$1.04
Book value per share
$7.71
Revenue per share
$5.01
TBVPS
$9.35
Balance sheet
Total assets
$3.07B
Total liabilities
$583.06M
Debt
$190.17M
Equity
$2.49B
Working capital
$1.29B
Liquidity
Debt to equity
0.08
Current ratio
4.99
Quick ratio
4.7
Net debt/EBITDA
-1.14
Margins
EBITDA margin
17%
Gross margin
96.4%
Net margin
11.3%
Operating margin
12.5%
Efficiency
Return on assets
6.3%
Return on equity
7.5%
Return on invested capital
11.5%
Return on capital employed
8.5%
Return on sales
14.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
-1.51%
1 week
2.75%
1 month
5.3%
1 year
-15.4%
YTD
14.03%
QTD
14.03%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$1.61B
Gross profit
$1.55B
Operating income
$201.48M
Net income
$182.28M
Gross margin
96.4%
Net margin
11.3%
Exelixis's operating income has decreased by 45% QoQ and by 30% YoY
EXEL's operating margin is down by 44% since the previous quarter and by 38% year-on-year
The company's net income fell by 41% QoQ and by 21% YoY
The net margin has decreased by 40% from the previous quarter and by 30% YoY

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
P/E
32.09
P/B
2.37
P/S
3.65
EV/EBIT
23.97
EV/EBITDA
20.53
EV/Sales
3.49
The company's EPS fell by 41% QoQ and by 22% YoY
The P/E is 40% above the last 4 quarters average of 23.3 and 12% above the 5-year quarterly average of 29.1
EXEL's P/B is 41% below its 5-year quarterly average of 4.1 and 3.6% below its last 4 quarters average of 2.5
The company's equity rose by 13% YoY
EXEL's price to sales (P/S) is 40% lower than its 5-year quarterly average of 6.2 and 2.4% lower than its last 4 quarters average of 3.8
The revenue has grown by 12% YoY

Efficiency

How efficient is Exelixis business performance
The ROIC has contracted by 45% from the previous quarter and by 37% YoY
The ROA has contracted by 43% from the previous quarter and by 34% YoY
The company's return on equity fell by 43% QoQ and by 33% YoY
The company's return on sales fell by 38% QoQ and by 29% YoY

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's total liabilities is up by 44% year-on-year and by 24% since the previous quarter
EXEL's quick ratio is down by 20% since the previous quarter and by 9% year-on-year
The debt is 92% less than the equity
The company's debt to equity rose by 33% QoQ
The debt has increased by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.